IMNM vs. OCUL, ABVX, SPRY, ARQT, OPK, PRAX, TYRA, SAVA, ETNB, and ALXO
Should you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Ocular Therapeutix (OCUL), ABIVAX Société Anonyme (ABVX), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), Praxis Precision Medicines (PRAX), Tyra Biosciences (TYRA), Cassava Sciences (SAVA), 89bio (ETNB), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Ocular Therapeutix has a net margin of -192.61% compared to Ocular Therapeutix's net margin of -761.92%. Ocular Therapeutix's return on equity of -69.74% beat Immunome's return on equity.
In the previous week, Ocular Therapeutix had 18 more articles in the media than Immunome. MarketBeat recorded 22 mentions for Ocular Therapeutix and 4 mentions for Immunome. Ocular Therapeutix's average media sentiment score of 0.65 beat Immunome's score of -0.21 indicating that Immunome is being referred to more favorably in the news media.
Ocular Therapeutix presently has a consensus target price of $15.17, suggesting a potential upside of 167.96%. Immunome has a consensus target price of $30.50, suggesting a potential upside of 96.77%. Given Immunome's higher probable upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Immunome.
Ocular Therapeutix received 403 more outperform votes than Immunome when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 67.65% of users gave Immunome an outperform vote.
Ocular Therapeutix has higher revenue and earnings than Immunome. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 5.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 20.0% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Ocular Therapeutix has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500.
Summary
Ocular Therapeutix and Immunome tied by winning 9 of the 18 factors compared between the two stocks.
Get Immunome News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunome Competitors List
Related Companies and Tools
